INCY Valuation
Incyte Corp
$
85.850
- Overview
- Forecast
- Valuation
- Earnings
INCY Relative Valuation
INCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INCY is overvalued; if below, it's undervalued.
Historical Valuation
Incyte Corp (INCY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 12.22 is considered Undervalued compared with the five-year average of 20.31. The fair price of Incyte Corp (INCY) is between 127.45 to 210.84 according to relative valuation methord. Compared to the current price of 81.61 USD , Incyte Corp is Undervalued By 35.97%.
Relative Value
Fair Zone
127.45-210.84
Current Price：81.61
35.97%
Undervalued
12.83
PE
1Y
3Y
5Y
Trailing
Forward
8.38
EV/EBITDA
Incyte Corp. (INCY) has a current EV/EBITDA of 8.38. The 5-year average EV/EBITDA is 16.78. The thresholds are as follows: Strongly Undervalued below -1.60, Undervalued between -1.60 and 7.59, Fairly Valued between 25.97 and 7.59, Overvalued between 25.97 and 35.15, and Strongly Overvalued above 35.15. The current Forward EV/EBITDA of 8.38 falls within the Historic Trend Line -Fairly Valued range.
8.40
EV/EBIT
Incyte Corp. (INCY) has a current EV/EBIT of 8.40. The 5-year average EV/EBIT is 18.27. The thresholds are as follows: Strongly Undervalued below 1.86, Undervalued between 1.86 and 10.06, Fairly Valued between 26.47 and 10.06, Overvalued between 26.47 and 34.67, and Strongly Overvalued above 34.67. The current Forward EV/EBIT of 8.40 falls within the Undervalued range.
3.15
PS
Incyte Corp. (INCY) has a current PS of 3.15. The 5-year average PS is 4.36. The thresholds are as follows: Strongly Undervalued below 1.61, Undervalued between 1.61 and 2.99, Fairly Valued between 5.74 and 2.99, Overvalued between 5.74 and 7.12, and Strongly Overvalued above 7.12. The current Forward PS of 3.15 falls within the Historic Trend Line -Fairly Valued range.
12.34
P/OCF
Incyte Corp. (INCY) has a current P/OCF of 12.34. The 5-year average P/OCF is 19.93. The thresholds are as follows: Strongly Undervalued below 5.03, Undervalued between 5.03 and 12.48, Fairly Valued between 27.38 and 12.48, Overvalued between 27.38 and 34.82, and Strongly Overvalued above 34.82. The current Forward P/OCF of 12.34 falls within the Undervalued range.
12.25
P/FCF
Incyte Corp. (INCY) has a current P/FCF of 12.25. The 5-year average P/FCF is 27.46. The thresholds are as follows: Strongly Undervalued below -6.03, Undervalued between -6.03 and 10.71, Fairly Valued between 44.21 and 10.71, Overvalued between 44.21 and 60.95, and Strongly Overvalued above 60.95. The current Forward P/FCF of 12.25 falls within the Historic Trend Line -Fairly Valued range.
Incyte Corp (INCY) has a current Price-to-Book (P/B) ratio of 3.75. Compared to its 3-year average P/B ratio of 3.45 , the current P/B ratio is approximately 8.66% higher. Relative to its 5-year average P/B ratio of 4.45, the current P/B ratio is about -15.70% higher. Incyte Corp (INCY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 3.28%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 2.72% , the current FCF yield is about -100.00% lower.
3.94
P/B
Median3y
3.45
Median5y
4.45
6.01
FCF Yield
Median3y
3.28
Median5y
2.72
Competitors Valuation Multiple
The average P/S ratio for INCY's competitors is 4.03, providing a benchmark for relative valuation. Incyte Corp Corp (INCY) exhibits a P/S ratio of 3.15, which is -21.87% above the industry average. Given its robust revenue growth of 16.46%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of INCY increased by 24.29% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 6.77 to 19.37.
The secondary factor is the Revenue Growth, contributed 16.46%to the performance.
Overall, the performance of INCY in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
PFGC
Performance Food Group Co
101.270
USD
+2.96%
UDR
UDR Inc
38.500
USD
+1.77%
BSY
Bentley Systems Inc
52.090
USD
-0.53%
DVA
DaVita Inc
134.690
USD
+1.98%
AKAM
Akamai Technologies Inc
75.440
USD
+4.82%
GFI
Gold Fields Ltd
30.240
USD
-3.60%
UNM
Unum Group
71.010
USD
+0.95%
AU
Anglogold Ashanti PLC
55.790
USD
-2.55%
FTI
TechnipFMC PLC
35.020
USD
-0.28%
PKX
Posco Holdings Inc
56.390
USD
+0.86%
FAQ
Is Incyte Corp (INCY) currently overvalued or undervalued?
Incyte Corp (INCY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 12.22 is considered Undervalued compared with the five-year average of 20.31. The fair price of Incyte Corp (INCY) is between 127.45 to 210.84 according to relative valuation methord. Compared to the current price of 81.61 USD , Incyte Corp is Undervalued By 35.97% .
What is Incyte Corp (INCY) fair value?
How does INCY's valuation metrics compare to the industry average?
What is the current P/B ratio for Incyte Corp (INCY) as of Aug 13 2025?
What is the current FCF Yield for Incyte Corp (INCY) as of Aug 13 2025?
What is the current Forward P/E ratio for Incyte Corp (INCY) as of Aug 13 2025?